Role of circulating tumor cell spheroids in drug resistance

Abstract

Cancer cell spheroids are used for drug screening as these three-dimensional (3D) assemblies recapitulate tumors more realistic than the widely employed 2D in vitro cultures. Limited drug diffusion and gradients of oxygen and nutrients in spheroids represent avascular tumor regions containing quiescent and hypoxic tumor cells with high drug resistance. Circulating tumor cells (CTCs) effect metastatic spread and are present in high numbers in malignant diseases such as small-cell lung cancer (SCLC) and in other cancer patients with high tumor load. CTCs are heterogeneous and only a small fraction of these cells survive in the circulation and cause distal lesions. CTCs may circulate as single cells but small CTC clusters or CTC spheroids have been detected in cancer patients and demonstrated to possess increased metastatic potential. At our lab we have obtained 9 permanent SCLC CTC cell lines (BHGc7, BHGc10, BHGc16, BHGc26, BHGc27, BHGc50, BHGc59, BHGc71, and UHGc5) of distinct patients exhibiting similar characteristics and spontaneous formation of large spheroids, termed tumorospheres. These aggregates were shown to exhibit high drug resistance compared to the corresponding single cell suspensions. The increased metastatic capability of small circulating tumor clusters/spheroids may be explained by their role as putative precursors of tumorospheres eventually trapped in capillaries. Limited drug penetration and the presence of hypoxic/quiescent cells can readily account for the global drug resistance of advanced SCLC which has resulted in clinical failure of a wide range of chemotherapeutics and low survival. Furthermore, we have detected such tumorospheres in non-small-cell lung cancer (NSCLC) patients progressing under EGFR-directed tyrosine kinase inhibitor therapy which had undergone NSCLC-SCLC transformation.

Keywords

Cancer / spheroid / circulating tumor cells / small cell lung cancer / non-small-cell lung cancer / transformation / dormancy

References

[1] Siegel RL,Jemal A.Cancer statistics, 2018..CA Cancer J Clin2018;68:7-30

[2] Housman G,Heerboth S,Longacre M.Drug resistance in cancer: an overview..Cancers (Basel)2014;6:1769-92 PMCID:PMC4190567

[3] Jo Y,Kim K,Choi J.Chemoresistance of cancer cells: requirements of tumor microenvironment-mimicking in vitro models in anti-cancer drug development..Theranostics2018;8:5259-75 PMCID:PMC6276092

[4] O’Connor JP,Waterton JC,Parker GJ.Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome..Clin Cancer Res2015;21:249-57 PMCID:PMC4688961

[5] Stock K,Vidic S,Rudisch A.Capturing tumor complexity in vitro: comparative analysis of 2D and 3D tumor models for drug discovery..Sci Rep2016;6:28951 PMCID:PMC4929472

[6] Moreno L.How can attrition rates be reduced in cancer drug discovery?.Expert Opin Drug Discov2013;8:363-8

[7] Carragher N,Tesei A,Bickle M.Concerns, challenges and promises of high-content analysis of 3D cellular models..Nat Rev Drug Discov2018;17:606

[8] Nunes AS,Costa EC,Correia IJ.3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs..Biotechnol Bioeng2019;116:206-26

[9] Ferreira LP,Mano JF.Design of spherically structured 3D in vitro tumor models - advances and prospects..Acta Biomater2018;75:11-34

[10] Sutherland RM.Cell and environment interactions in tumor microregions: the multicell spheroid model..Science1988;240:177-84

[11] Nath S.Three-dimensional culture systems in cancer research: focus on tumor spheroid model..Pharmacol Ther2016;163:94-108 PMCID:PMC4961208

[12] Grimes DR,Bloch K.A method for estimating the oxygen consumption rate in multicellular tumor spheroids..J R Soc Interface2014;11:20131124 PMCID:PMC3899881

[13] Groebe K.On the relation between size of necrosis a diameter of tumor spheroids..Int J Radiat Oncol Biol Phys1996;34:395-401

[14] Friedrich J,Ebner R.Spheroid-based drug screen: considerations and practical approach..Nat Protoc2009;4:309-24

[15] Höckel M.Biological consequences of tumor hypoxia..Semin Oncol2001;28:36-41

[16] Minchinton AI.Drug penetration in solid tumours..Nat Rev Cancer2006;6:583-92

[17] Rodrigues T,Silva-Correia J,Oliveira JM.Emerging tumor spheroids technologies for 3D in vitro cancer modeling..Pharmacol Ther2018;184:201-11

[18] Achilli TM,Meyer J,Morgan JR.Multilayer spheroids to quantify drug uptake and diffusion in 3D..Mol Pharm2014;11:2071-81 PMCID:PMC4096226

[19] Lazzari G,Matsusaki M,Couvreur P.Multicellular spheroid based on a triple co-culture: a novel 3D model to mimic pancreatic tumor complexity..Acta Biomater2018;78:296-307

[20] Benton G,George J,Koblinski J.Matrigel: from discovery and ECM mimicry to assays and models for cancer research..Adv Drug Deliv Rev2014;79-80:3-18

[21] Mittler F,Rulina AV,Gidrol X.High-content monitoring of drug effects in a 3D spheroid model..Front Oncol2017;7:293 PMCID:PMC5732143

[22] Hamilton G.Applicability of tumor spheroids for in vitro chemosensitivity assays..Expert Opin Drug Metab Toxicol2019;15:15-23

[23] Zanoni M,Arienti C,Tesei A.Anticancer drug discovery using multicellular tumor spheroid models..Expert Opin Drug Discov2019;14:289-301

[24] Lheureux S,Vergote I.Epithelial ovarian cancer..Lancet2019;393:1240-53

[25] Shield K,Ahmed N.Multicellular spheroids in ovarian cancer metastases: biology and pathology..Gynecol Oncol2009;113:143-8

[26] Al Habyan S,Szymborski J.Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer..Oncogene2018;37:5127-35 PMCID:PMC6137025

[27] Casey RC,Skubitz KM,Oegema TR Jr.Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids..Am J Pathol2001;159:2071-80 PMCID:PMC1850600

[28] Raghavan S,Ward MR,Fleck EMA.Personalized medicine-based approach to model patterns of chemoresistance and tumor recurrence using ovarian cancer stem cell spheroids..Clin Cancer Res2017;23:6934-45 PMCID:PMC6330017

[29] Gouvinhas C,Oliveira D,Castelo-Branco P.Lung cancer: a brief review of epidemiology and screening..Future Oncol2018;14:567-75

[30] Mancini R,De Vitis C,Roscilli G.Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment..PLoS One2011;6:e21320 PMCID:PMC3138755

[31] Meijer TG,Jager A.Ex vivo tumor culture systems for functional drug testing and therapy response prediction..Future Sci OA2017;3:FSO190 PMCID:PMC5481868

[32] Bielsa S,Martínez M,Martín A.Prognostic significance of pleural fluid data in patients with malignant effusion..Eur J Intern Med2008;19:334-9

[33] Endo H,Okuyama H,Uchida J.Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation..J Thorac Oncol2013;8:131-9

[34] Hamilton G,Plangger A.Implementation of functional precision medicine for anaplastic lymphoma kinase-arranged non-small cell lung cancer..Precis Cancer Med2019;

[35] Ruppen J,Marconi E,Schmid RA.A microfluidic platform for chemoresistive testing of multicellular pleural cancer spheroids..Lab Chip2014;14:1198-205

[36] Grimshaw MJ,Papazisis K,Bohnenkamp HR.Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells..Breast Cancer Res2008;10:R52 PMCID:PMC2481500

[37] Jeanes A,Yap AS.Cadherins and cancer: how does cadherin dysfunction promote tumor progression?.Oncogene2008;27:6920-9 PMCID:PMC2745643

[38] Aggarwal C,Ranganathan A,Troxel A.Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy..Lung Cancer2017;112:118-25

[39] Aceto N,Miyamoto DT,Wittner BS.Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis..Cell2014;158:1110-22 PMCID:PMC4149753

[40] Hong Y,Zhang Q.Circulating tumor cell clusters: What we know and what we expect (Review)..Int J Oncol2016;49:2206-16 PMCID:PMC5117994

[41] Hou JM,Lancashire L,Backen A.Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer..J Clin Oncol2012;30:525-32

[42] Gkountela S,Szczerba BM,Landin J.Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding..Cell2019;176:98-112.e14 PMCID:PMC6363966

[43] Yu M.Metastasis stemming from circulating tumor cell clusters..Trends Cell Biol2019;29:275-6

[44] Meng S,Frenkel EP,Naftalis EZ.Circulating tumor cells in patients with breast cancer dormancy..Clin Cancer Res2004;10:8152-62

[45] Liotta LA,Saidel GM.Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation..Cancer Res1974;34:997-1004

[46] Knisely WH.Relationship between size and distribution of spontaneous metastases and three sizes of intravenously injected particles of VX2 carcinoma..Cancer Res1958;18:900-5

[47] Peeters DJ,Van den Eynden GG,Onstenk W.Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer..Cancer Lett2015;356:872-9

[48] Liotta LA,Kleinerman J.The significance of hematogenous tumor cell clumps in the metastatic process..Cancer Res1976;36:889-94

[49] Hamilton G.Circulating tumor cells in the parallel invasion model supporting early metastasis..Oncomedicine2018;3:15-27

[50] Semenova EA,Berns A.Origins, genetic landscape, and emerging therapies of small cell lung cancer..Genes Dev2015;29:1447-62 PMCID:PMC4526731

[51] Hamilton G.Immunotherapy for small cell lung cancer: mechanisms of resistance..Expert Opin Biol Ther2019;19:423-32

[52] Koinis F,Georgoulias V.Small cell lung cancer (SCLC): no treatment advances in recent years..Transl Lung Cancer Res2016;5:39-50 PMCID:PMC4758968

[53] Weiswald LB,Dangles-Marie V.Spherical cancer models in tumor biology..Neoplasia2015;17:1-15 PMCID:PMC4309685

[54] Klameth L,Hochmaier M,Redl M.Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance..Sci Rep2017;7:5337 PMCID:PMC5509650

[55] Hamilton G,Rath B,Zeillinger R.Small cell lung cancer: circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype..Cell Adh Migr2016;10:360-7 PMCID:PMC4986707

[56] Rath B,Plangger A,Ulsperger E.Expression of proteolytic enzymes by small cell lung cancer circulating tumor cell lines..Cancers (Basel)2019;11:pii:E114 PMCID:PMC6357007

[57] Dorantes-Heredia R,Cano-García F.Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors..Transl Lung Cancer Res2016;5:401-12 PMCID:PMC5009079

[58] Roca E,Amoroso V,Ferrari V.Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: a systematic review and pooled analysis..Cancer Treat Rev2017;59:117-22

[59] Ahn S,Han J,Lee SH.Transformation to small cell lung cancer of pulmonary adenocarcinoma: clinicopathologic analysis of six cases..J Pathol Transl Med2016;50:258-63 PMCID:PMC4963973

[60] Abdallah N,Abdulfatah E,Wozniak AJ.Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation..Lung Cancer (Auckl)2018;9:85-90 PMCID:PMC6207227

[61] Norkowski E,Lacroix L,Fadel É.Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology..J Thorac Oncol2013;8:1265-71

[62] Attili I,Conte P,Rosell R.Therapeutic approaches for T790M mutation positive non-small-cell lung cancer..Expert Rev Anticancer Ther2018;18:1021-30

[63] Sequist LV,Dias-Santagata D,Turke AB.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors..Sci Transl Med2011;3:75ra26 PMCID:PMC3132801

[64] Yu HA,Rekhtman N,Zakowski MF.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers..Clin Cancer Res2013;19:2240-7 PMCID:PMC3630270

[65] Zakowski MF,Kris MG.EGFR mutations in small-cell lung cancers in patients who have never smoked..N Engl J Med2006;355:213-5

[66] van Riel S,Heideman D,Biesma B.A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation..Ann Oncol2012;23:3188-9

[67] Watanabe S,Matsui T,Tani M.Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma..Lung Cancer2013;82:370-2

[68] Ferrer L,Brevet M,Mazieres J.A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics..J Thorac Oncol2019;14:130-4

[69] Oser MG,Sequist LV.Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin..Lancet Oncol2015;16:e165-72 PMCID:PMC4470698

[70] Adelstein DJ,Snow NJ,Hines JD.Mixed small cell and non-small cell lung cancer..Chest1986;89:699-704

[71] Mangum MD,Hainsworth JD,Johnson DH.Combined small-cell and non-small-cell lung cancer..J Clin Oncol1989;7:607-12

[72] Shiao TH,Yu CJ,Hsu YC.Epidermal growth factor receptor mutations in small cell lung cancer: a brief report..J Thorac Oncol2011;6:195-8

[73] Yang H,Zhou C,Hu Y.The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer..Medicine (Baltimore)2019;98:e14893

[74] Zhang W,Wang H,Zhang XH.Bone metastasis: find your niche and fit in..Trends Cancer2019;5:95-110 PMCID:PMC6383208

[75] Endo H.Dormancy in cancer..Cancer Sci2019;110:474-80 PMCID:PMC6361606

[76] Riffle S.Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids..J Exp Clin Cancer Res2017;36:102 PMCID:PMC5543535

[77] Hamilton G,Hochmair M.Metastasis: Circulating tumor cells in small cell lung cancer..Trends Cancer2016;2:159-60

[78] Denes V,Makarovskiy A,Szappanos S.Metastasis blood test by flow cytometry: in vivo cancer spheroids and the role of hypoxia..Int J Cancer2015;136:1528-36

[79] Ishiguro T,Sato A,Enomoto T.Tumor-derived spheroids: relevance to cancer stem cells and clinical applications..Cancer Sci2017;108:283-9 PMCID:PMC5378268

[80] Jolly MK,Debeb BG,Farach-Carson MC.Inflammatory breast cancer: a model for investigating cluster-based dissemination..NPJ Breast Cancer2017;3:21 PMCID:PMC5460282

[81] Au SH,Moore JC,Chen YL.Clusters of circulating tumor cells traverse capillary-sized vessels..Proc Natl Acad Sci U S A2016;113:4947-52 PMCID:PMC4983862

[82] Zheng X,Kim J,Kaye J.Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer..Nature2015;527:525-30 PMCID:PMC4849281

[83] Lu W.Epithelial-mesenchymal plasticity in cancer progression and metastasis..Dev Cell2019;49:361-74 PMCID:PMC6506183

[84] Rath B,Plangger A,Ulsperger E.Expression of proteolytic enzymes by small cell lung cancer circulating tumor cell lines..Cancers (Basel)2019;11:pii:E114 PMCID:PMC6357007

[85] Tellez-Gabriel M,Cadé M,Heymann MF.Circulating tumor cell-derived pre-clinical models for personalized medicine..Cancers (Basel)2018;11:pii:E19 PMCID:PMC6356998